MMWR Recomm Rep. 1995 Sep 22;44(RR-12):1-13.
Since 1989, a rapid increase in the incidence of infection and colonization with vancomycin-resistant enterococci (VRE) has been reported by U.S. hospitals. This increase poses important problems, including a) the lack of available antimicrobial therapy for VRE infections, because most VRE are also resistant to drugs previously used to treat such infections (e.g., aminoglycosides and ampicillin), and b) the possibility that the vancomycin-resistant genes present in VRE can be transferred to other gram-positive microorganisms (e.g., Staphylococcus aureus). An increased risk for VRE infection and colonization has been associated with previous vancomycin and/or multiantimicrobial therapy, severe underlying disease or immunosuppression, and intraabdominal surgery. Because enterococci can be found in the normal gastrointestinal and female genital tracts, most enterococcal infections have been attributed to endogenous sources within the individual patient. However, recent reports of outbreaks and endemic infections caused by enterococci, including VRE, have indicated that patient-to-patient transmission of the microorganisms can occur either through direct contact or through indirect contact via a) the hands of personnel or b) contaminated patient-care equipment or environmental surfaces. This report presents recommendations of the Hospital Infection Control Practices Advisory Committee for preventing and controlling the spread of vancomycin resistance, with a special focus on VRE. Preventing and controlling the spread of vancomycin resistance will require coordinated, concerted efforts from all involved hospital departments and can be achieved only if each of the following elements is addressed: a) prudent vancomycin use by clinicians, b) education of hospital staff regarding the problem of vancomycin resistance, c) early detection and prompt reporting of vancomycin resistance in enterococci and other gram-positive microorganisms by the hospital microbiology laboratory, and d) immediate implementation of appropriate infection-control measures to prevent person-to-person transmission of VRE.
自1989年以来,美国医院报告万古霉素耐药肠球菌(VRE)感染和定植的发生率迅速上升。这种上升带来了重要问题,包括:a)缺乏针对VRE感染的有效抗菌治疗,因为大多数VRE对以前用于治疗此类感染的药物(如氨基糖苷类和氨苄西林)也耐药;b)VRE中存在的万古霉素耐药基因可能转移到其他革兰氏阳性微生物(如金黄色葡萄球菌)的可能性。VRE感染和定植风险增加与先前使用万古霉素和/或多种抗菌药物治疗、严重基础疾病或免疫抑制以及腹部手术有关。由于肠球菌可在正常胃肠道和女性生殖道中发现,大多数肠球菌感染被认为是个体患者内源性感染源所致。然而,最近关于包括VRE在内的肠球菌引起的暴发和地方性感染的报告表明,微生物可通过直接接触或通过以下间接接触在患者之间传播:a)医护人员的手;b)受污染的患者护理设备或环境表面。本报告提出了医院感染控制实践咨询委员会关于预防和控制万古霉素耐药性传播的建议,特别关注VRE。预防和控制万古霉素耐药性传播需要所有相关医院科室的协调一致努力,只有解决以下每个要素才能实现:a)临床医生谨慎使用万古霉素;b)对医院工作人员进行万古霉素耐药性问题教育;c)医院微生物实验室早期检测并及时报告肠球菌和其他革兰氏阳性微生物中的万古霉素耐药性;d)立即实施适当的感染控制措施以防止VRE在人与人之间传播。